Stay updated with breaking news from Dose Ranging Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Three late-breaking presentations in vitiligo highlight new long-term data from the Phase 3 TRuE-V trials for Opzelura (ruxolitinib) cream and results from a Phase 2b study with povorcitinib (INCB54707)
Data presentations provide key updates on the portfolio, including Botulinum Toxin, Belotero, Radiesse and Ultherapy Merz Aesthetics today confirmed its commitment as a global leader in medical aesthetics
Data presentations provide key updates on the portfolio, including Botulinum Toxin, Belotero, Radiesse and Ultherapy Merz Aesthetics today confirmed its commitment as a global leader in medical aesthetics
/PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful...
/PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful...